Compare Stocks: SPRB, AVDL, and SIGA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$21.39 -1.1%	$21.48	$8.19 ▼ $23.57	$2.09B	1.31	2.03 million shs	35.02 million shs
SIGA Siga Technologies	$3.06	$3.37	$2.83 ▼ $9.45	$219.86M	0.97	664,490 shs	568,566 shs
SPRB Spruce Biosciences	$60.78 -4.0%	$49.83	$7.00 ▼ $240.00	$174.68M	3.23	57,624 shs	39,960 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+43.85%
SIGA Siga Technologies	0.00%	+0.66%	-5.85%	-34.62%	-62.91%
SPRB Spruce Biosciences	0.00%	+17.84%	+40.14%	+18.55%	+699.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$21.39 -1.1%	$21.48	$8.19 ▼ $23.57	$2.09B	1.31	2.03 million shs	35.02 million shs
SIGA Siga Technologies	$3.06	$3.37	$2.83 ▼ $9.45	$219.86M	0.97	664,490 shs	568,566 shs
SPRB Spruce Biosciences	$60.78 -4.0%	$49.83	$7.00 ▼ $240.00	$174.68M	3.23	57,624 shs	39,960 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+43.85%
SIGA Siga Technologies	0.00%	+0.66%	-5.85%	-34.62%	-62.91%
SPRB Spruce Biosciences	0.00%	+17.84%	+40.14%	+18.55%	+699.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	1.91	Reduce	$20.20	-5.56% Downside
SIGA Siga Technologies	1.00	Sell	N/A	N/A
SPRB Spruce Biosciences	2.75	Moderate Buy	$159.50	162.42% Upside

Current Analyst Ratings Breakdown

Latest SPRB, AVDL, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	SPRB Spruce Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$123.00 ➝ $104.00
8/13/2026	SPRB Spruce Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight
8/13/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$150.00 ➝ $144.00
8/12/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/13/2026	SPRB Spruce Biosciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$160.00
7/1/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
6/16/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$123.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$248.52M	8.41	N/A	N/A	$0.77 per share	27.78
SIGA Siga Technologies	$94.57M	2.32	$0.33 per share	9.19	$2.30 per share	1.33
SPRB Spruce Biosciences	$4.91M	35.53	N/A	N/A	$29.13 per share	2.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	N/A	N/A	356.50	N/A	-0.11%	-0.33%	-0.15%	N/A
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)

Latest SPRB, AVDL, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.76	2.37
SIGA Siga Technologies	N/A	21.72	16.48
SPRB Spruce Biosciences	0.05	9.23	9.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
SIGA Siga Technologies	55.40%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
SIGA Siga Technologies	2.73%
SPRB Spruce Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	97.66 million	92.58 million	Optionable
SIGA Siga Technologies	40	71.85 million	69.89 million	Optionable
SPRB Spruce Biosciences	20	2.87 million	2.75 million	Optionable

SPRB, AVDL, and SIGA Headlines

Recent News About These Companies

HC Wainwright Issues Pessimistic Outlook for SPRB Earnings

August 30 at 1:13 AM | americanbankingnews.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $159.50 Average PT from Analysts

August 29 at 3:29 AM | americanbankingnews.com

Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

August 28 at 6:08 PM | theglobeandmail.com

Q3 EPS Estimates for Spruce Biosciences Cut by HC Wainwright

August 28 at 7:11 AM | marketbeat.com

Spruce Biosciences stock gains after analyst backs regulatory progress

August 27 at 10:03 AM | finance.yahoo.com

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026 | finance.yahoo.com

AWM Investment Company Inc. Makes New $7.94 Million Investment in Spruce Biosciences, Inc. $SPRB

August 26, 2026 | marketbeat.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 24, 2026 | marketbeat.com

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026 | finance.yahoo.com

Spruce Biosciences Inc.

August 16, 2026 | marketwatch.com

Spruce Biosciences (NASDAQ:SPRB) Downgraded to Strong Sell Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp

August 13, 2026 | marketbeat.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026 | aol.comA

Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS

August 12, 2026 | marketbeat.com

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026 | finance.yahoo.com

Spruce Biosciences (SPRB) to Announce Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 3, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026 | finance.yahoo.com

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

July 27, 2026 | tipranks.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 8, 2026 | finance.yahoo.com

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

July 8, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, AVDL, and SIGA Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Siga Technologies NASDAQ:SIGA

$3.06 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Spruce Biosciences NASDAQ:SPRB

$60.78 -2.52 (-3.98%)

As of 08/28/2026 04:00 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRB, AVDL, and SIGA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRB, AVDL, and SIGA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRB, AVDL, and SIGA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, AVDL, and SIGA Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

Siga Technologies NASDAQ:SIGA

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRB, AVDL, and SIGA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRB, AVDL, and SIGA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRB, AVDL, and SIGA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, AVDL, and SIGA Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

Siga Technologies NASDAQ:SIGA

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools